Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Neoplasms benign, malignant and unspecified (incl cysts and polyps) – page 98

  • 3 926 clinical trials
  • 1 543 recruiting
  • 706 conditions
  • 31 countries

Conditions in this area

706 conditions with trials, the busiest first

Non-small cell lung cancer332Breast cancer170Plasma cell myeloma164Neoplasm158Acute myeloid leukaemia132Neoplasm malignant129Colorectal cancer metastatic106Prostate cancer102Colorectal cancer90Ovarian cancer90Hepatocellular carcinoma89Breast cancer metastatic84Non-small cell lung cancer metastatic82Chronic lymphocytic leukaemia80Malignant melanoma79Triple negative breast cancer69Squamous cell carcinoma of head and neck68Hormone receptor positive HER2 negative breast cancer62Non-small cell lung cancer stage IV59Pancreatic carcinoma57Hormone-refractory prostate cancer56Bladder cancer55Gastric cancer55Endometrial cancer53+682

Clinical trials in Neoplasms benign, malignant and unspecified (incl cysts and polyps)

3 926 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

3 926 clinical trials

Colorectal cancer metastatic

Recruiting

Study on Intermittent vs. Continuous Panitumumab and FOLFIRI for Patients with Unresectable Left-Sided Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Panitumumab
  • Sponsor:IRCCS Istituto Nazionale Tumori Fondazione Pascale

Metastases to peritoneum

Recruiting

Study of Radium-224 in Patients with Advanced Ovarian, Fallopian Tube, or Peritoneal Cancer with Peritoneal Metastasis Undergoing Chemotherapy and Surgery

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:RADIUM-224 adsorbed in calcium carbonate microparticles
  • Sponsor:Oncoinvent Solutions AS

T-cell type acute leukaemia+1

Recruiting

Study of CD7-CART01, Cyclophosphamide, and Fludarabine Phosphate for Children and Young Adults with Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:CD7-CART01
  • Sponsor:Ospedale Pediatrico Bambino Gesu'

Sarcoma

Recruiting

Study of Activated NK Cells for Treating Sarcomas in Children, Adolescents, and Young Adults

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years
  • Substances:Allogeneic Peripheral Blood-Derived Cd56+ Natural Killer Cells, Co-Cultured With K562-Mb15-41Bbi Cell Line
  • Sponsor:Hospital Universitario La Paz

Pancreatic carcinoma

Recruiting

Study on Pancreas Removal and Islet Cell Transplant for Patients with Pancreatic Cancer at High Risk of Post-Surgery Leaks

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Autologous Pancreatic Islets
  • Sponsor:Technische Universitat Dresden

Neoplasm malignant

Recruiting

Study on BI-1808 and Pembrolizumab for Patients with Advanced Solid Tumors

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:BI-1808
  • Sponsor:Bioinvent International AB

Study on Everolimus and Lutetium (177Lu) Oxodotreotide for Treating Grades 2 and 3 Refractory Meningioma in Patients

Recruiting
Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Everolimus
  • Sponsor:CHRU De Nancy

Bladder transitional cell carcinoma

Recruiting

Study on Bladder Cancer: Testing Cisplatin and Drug Combination for Patients with Non-Muscle Invasive Bladder Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Hospital Universitario La Paz

Non-small cell lung cancer

Recruiting

Study of NVL-520 for Patients with Advanced ROS1-Positive Lung Cancer and Other Solid Tumors

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Zidesamtinib
  • Sponsor:Nuvalent Inc.

Endometrial cancer+4

Recruiting

Study of PC14586 for Patients with Advanced Solid Tumors with a Specific TP53 Mutation

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:PC14586
  • Sponsor:Pmv Pharmaceuticals Inc.

Malignant melanoma stage III

Recruiting

Study of LTX-315 and Pembrolizumab for Patients with Resectable Stage III-IV Melanoma

InvestigationalNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Ruxotemitide
  • Sponsor:Oslo University Hospital HF

Metastases to liver+1

Recruiting

Study on Melphalan, Ipilimumab, and Nivolumab for Patients with Uveal Melanoma Liver Metastases

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Ipilimumab
  • Sponsor:Vaestra Goetalandsregionen

Substances studied in this area

The therapies tested most often in Neoplasms benign, malignant and unspecified (incl cysts and polyps) trials.

Pembrolizumab467 clinical trialsCarboplatin344 clinical trialsCisplatin288 clinical trialsPaclitaxel266 clinical trialsFluorouracil239 clinical trialsOxaliplatin230 clinical trialsNivolumab218 clinical trialsDexamethasone169 clinical trialsDurvalumab163 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.